Johnson & Johnson Symposium: AI Bringing Both Opportunity And Risk In Drug Development

Artificial intelligence is reshaping drug discovery, but its integration raises critical questions: How do we balance AI-driven insights with data integrity, human expertise, and ethical considerations? At a recent Johnson & Johnson symposium, experts explored AI’s role across the therapeutic pipeline from early-stage research to clinical trials and biopharma manufacturing. Discussions highlighted the need for scientists to pair coding skills with biological knowledge, the importance of inclusive trial design, and how AI can accelerate processes without replacing human judgment. Real-world examples from startups and major biopharma companies showcased AI’s potential to streamline workflows and improve success rates. As adoption grows, the challenge remains clear: leveraging technology without losing the human element.

Explore the insights shaping the future of life sciences.